Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Oculis Holding with an unchanged $26 price target, citing the advancement of privosegtor in optic neuritis and multiple sclerosis relapses. The FDA-supported PIONEER-1 study and Breakthrough Therapy designation support this view. Stifel Nicolaus also maintained a Buy rating with a $40 target.
Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Oculis Holding and keeping the price target at $26.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Yi Chen has given his Buy rating due to a combination of factors tied to Oculis’ advancing clinical and regulatory position for privosegtor. The company has initiated patient treatment in the pivotal PIONEER-1 optic neuritis study under an FDA Special Protocol Assessment, with Breakthrough Therapy and PRIME designations reinforcing the drug’s potential to become a first-in-class neuroprotective option.
In addition, Oculis is pursuing a capital-efficient expansion of privosegtor into acute multiple sclerosis relapses, leveraging existing optic neuritis data and an FDA-supported path that avoids new preclinical work. This dual-indication strategy, combined with the validated Phase 2 neuroprotective signal and streamlined development plan, underpins the unchanged $26 price target and supports maintaining a Buy recommendation.
In another report released on August 14, Stifel Nicolaus also maintained a Buy rating on the stock with a $40.00 price target.